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Patrick J. Stover3
Folate-mediated one-carbon metabolism (FOCM) is an interconnected network of metabolic 
pathways, including those required for the de novo synthesis of dTMP and purine nucleotides and 
for remethylation of homocysteine to methionine. Mouse models of folate-responsive neural tube 
defects (NTDs) indicate that impaired de novo thymidylate (dTMP) synthesis through changes in SHMT 
expression is causative in folate-responsive NTDs. We have created a hybrid computational model 
comprised of ordinary differential equations and stochastic simulation. We investigated whether the de 
novo dTMP synthesis pathway was sensitive to perturbations in FOCM that are known to be associated 
with human NTDs. This computational model shows that de novo dTMP synthesis is highly sensitive to 
the common MTHFR C677T polymorphism and that the effect of the polymorphism on FOCM is greater 
in folate deficiency. Computational simulations indicate that the MTHFR C677T polymorphism and 
folate deficiency interact to increase the stochastic behavior of the FOCM network, with the greatest 
instability observed for reactions catalyzed by serine hydroxymethyltransferase (SHMT). Furthermore, 
we show that de novo dTMP synthesis does not occur in the cytosol at rates sufficient for DNA 
replication, supporting empirical data indicating that impaired nuclear de novo dTMP synthesis results 
in uracil misincorporation into DNA.
Perturbations in folate-mediated one-carbon metabolism (FOCM) are associated with numerous pathologies 
including neural tube defects (NTDs)1, stroke2, colorectal and other types of cancer3–5. Furthermore, enzymes 
in FOCM have been successful targets for the development of antineoplastic pharmaceutical agents including-
0020methotrexate and 5-flurouracil6. FOCM in the cytoplasm is composed of three interconnected biosynthetic 
pathways, which include de novo thymidylate (dTMP) synthesis, de novo purine synthesis and homocysteine 
remethylation to methionine (Fig. 1). The FOCM network is sensitive to nutritional status for several vitamins 
that serve as enzyme cofactors (folate, riboflavin, vitamin B6 and vitamin B12) and genetic factors (coding and 
expression variants in folate-dependent enzymes) that can alter network outputs, including DNA synthesis, DNA 
repair and chromatin methylation7–9. Understanding the molecular basis of disease etiology has been limited 
by the ability to ascribe specific FOCM pathways and their biomarkers to clinical outcomes, because the path-
ways of FOCM are tightly interconnected8. FOCM complexity is manifest by: (a) competition among the path-
ways for a limiting pool of folate cofactors10, (b) long-range and indirect regulatory processes, (c) formation of 
multi-enzyme complexes, (d) cellular compartmentation, (e) interactions with other metabolic pathways, (f) 
nutritional status (g) penetrant genetic variants9, 11. Mathematical models have been developed to assess this 
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complexity and gain an understanding of the cause-and-effect relationships that regulate FOCM functioning in 
health and disease. The overall goal is to provide an understanding of function of the entire system in silico that 
can be used to accelerate discovery and guide the design of biological experimentation.
Early models of FOCM quantified steady-state concentrations of folates, and predicted how methotrexate and 
5-fluorouracil affect the rates of de novo purine and thymidylate biosynthesis in L1210 cells12–15. These models 
considered FOCM reactions as occurring in a common cellular compartment, described the reactions in terms 
of Michaelis-Menten kinetics, and investigated biological consequences of inhibiting de novo purine and dTMP 
biosynthesis. Other models have been constructed to simulate the homocysteine remethylation in liver16–18. 
Using data from experimental animals, non-trivial mathematical functions were adopted to address long-range 
inhibition and activation processes involving folates and other metabolites that cannot be translated into simple 
Michaelis-Menten equations17. These models can reproduce changes in metabolite concentrations in response to 
nutritional deficiencies and the effects of gene variants, thus corroborating human clinical and epidemiological 
data. These models have also integrated other pathways such as glutathione metabolism and polyamine synthesis, 
studying the influence of indirect effects beyond FOCM19, 20.
These existing FOCM models describe the continuous flux of metabolite concentrations in terms of ordinary 
differential equations (ODEs) with time as an independent variable13, 20. Sensitivity analysis is used to summa-
rize the effects on metabolite concentrations and reaction velocities in response to changes in inputs or enzyme 
activities21. Here we present a hybrid stochastic model for simulating the FOCM dynamics where state-of-the art 
deterministic simulation (based on ODEs) has been coupled with exact stochastic simulation to assess metabolite 
variabilities in the FOCM network at steady state. A detailed description of this combined approach can be found 
in Methods. The deterministic approach used in isolation can only provide a rough estimate of FOCM model 
dynamics, because the deterministic approach is limited when enzyme substrates, such as folate cofactors, are 
present in the cells at low micromolar concentrations, and because reactions within the network occur randomly 
at discrete time points. FOCM is expected to exhibit variability (i.e. stochasticity) in its behavior22. Capturing 
system stochasticity is essential when substrate concentrations are low and limiting, but requires consideration 
of molecules as discrete entities, rather than describing concentrations as continuous variables through ODEs23. 
Simulation strategies that combine both deterministic and stochastic approaches can give a more accurate and 
more detailed understanding of FOCM network functioning and stability. In contrast to approaches based solely 
on deterministic simulation, these studies can be used to assess the contributions of factors such as genetic vari-
ation and nutritional status on the stochastic behavior of individual pathways within the network, thereby aiding 
in establishing which system inputs (i.e. nutrition) and outputs (i.e. biomarkers) are most closely associated with 
human health outcomes.
Dysregulation of the partitioning of one-carbon units in the form of 5,10-methylenetetrahydrofolate (CH2F) 
cofactors between the de novo dTMP biosynthesis and homocysteine remethylation pathways is believed to 
underlie FOCM-associated pathologies including NTDs (Fig. 1). A common variant of MTHFR, the C677T poly-
morphism, has been associated with numerous pathologies including birth defects, cancer, cardiovascular events, 
and other pathologies24. MTHFR catalyzes the FADH-dependent, irreversible conversion of CH2F to 5mTHF, 
which commits folate cofactors away from dTMP synthesis and towards homocysteine remethylation in the 
cytosol (Fig. 1). The variant results from an alanine to valine substitution in the protein that decreases MTHFR 
Figure 1. The reaction-based specification of the model according to the notation introduced in Gostner et 
al.61. Rectangles identify model variables, non-boxed substrates are model constants, green circles identify 
enzymes, dark blue arcs identify matter transformation, and light blue arcs identify regulatory events (dotted 
lines indicate activations and solid lines indicate inhibitions). The purple boxes indicate reactions and variables 
associated with the folate cycle and the homocysteine remethylation cycle, respectively.
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activity by decreasing its affinity for the FADH cofactor. Such substitution affects enzyme stability and hence 
the partitioning of folates between dTMP synthesis and homocysteine remethylation25, 26. Decreased MTHFR 
activity resulting from the polymorphism decreases 5mTHF synthesis, leading to impaired homocysteine remeth-
ylation and elevated serum homocysteine24. The 677 T variant is also associated with a redistribution of cellular 
folate cofactors; 5mTHF is the predominate form of folate in red blood cells in MTHFR 677CC carriers, whereas 
10fTHF is the predominate form of folate in MTHFR 677TT carriers27–29. 10fTHF is less chemically stable than 
5mTHF, and the MTHFR 677TT variant is associated with lower folate status30 and higher folate requirement31. 
Recent studies suggest that the contribution of the MTHFR variant to NTD risk is due to its impact on cellular 
folate status, rather than impaired homocysteine remethylation32. Likewise, mouse models of NTDs indicate that 
impaired dTMP synthesis, and not homocysteine remethylation, cause folate-responsive NTDs33–35. Reed et al. 
investigated the consequences of the MTHFR C677T polymorphism, assuming 70% enzyme activity for hete-
rozygote and 30% enzyme activity for homozygote, in comparison to CC homozygotes (which was set to 100% 
activity) using parameters for folate monoglutamates, which are not the physiological form of folate cofactors in 
cells. Under these conditions, the variant allele decreased concentrations of 5mTHF and SAM and increased the 
concentrations of homocysteine, SAH, and rates of dTMP and purine biosynthesis21, which is inconsistent with 
current understanding of biochemical changes associated with NTD risk. The effect on the redistribution of folate 
cofactors towards 10fTHF that is associated with the 677 T variant, or its impact on other pathways within the 
network, was not reported21.
Here, we studied the partitioning of CH2F, a cofactor for both homocysteine remethylation and de novo 
dTMP biosynthesis36–38, and the effects of known genetic and nutritional variables that impact movement of 
CH2F through the network. Existing models are limited by adopting kinetic parameters determined from the 
use of folate monoglutamate substrates19, 20. Folate polyglutamates are the functional form of folate cofactors 
in cells and have much higher affinity for their respective FOCM enzymes than the corresponding monoglu-
tamate forms of folate39, 40. Therefore, we updated the parameters in the deterministic model to include the 
physiologically-relevant polyglutamate forms of folate cofactors and demonstrate that it faithfully recapitulates 
existing data in the literature (see Methods, Model Validation and Fig. 2). The decisions for selecting individual 
enzyme kinetic parameters for this model were driven by: 1) available data for physiologically relevant polygluta-
mate forms of the folate cofactors derived from characterization of mammalian enzymes, and 2) data from human 
models, specifically L1210 cells, because of the richness and quality of the data used to derive kinetic parameters. 
Given the high conservation of folate enzymes among mammals, our model could be applied to mammalian 
systems in general, even though we are not proposing a completely homogeneous model with respect to species.
We were able to identify key nodes in the network of Fig. 1 that exhibit high degrees of stochastic behavior, 
including the influence of nutrient status and genetic variation on stochasticity through simulations. We explored 
the impact of the MTHFR C677T polymorphism and its interaction with folate status on partitioning of CH2F 
within the network, including its impact on de novo dTMP biosynthesis to understand the etiology of NTDs. 
The results of the computational model provide evidence that the rates of de novo dTMP synthesis as currently 
modeled in the cytosol are insufficient to support DNA synthesis in S-phase in mammals, accounting for uracil 
misincorporation into DNA that occurs in folate deficiency and in mouse models of NTDs.
Results
The effect of folate status and the MTHFR polymorphism on pathways affecting NTD risk. In 
the current model, MTHFR activity was decreased to model the effect of the MTHFR C677T polymorphism. In 
addition, a two-fold increase in MTHFR activity was modeled to examine whether there was a dose-response 
relationship between MTHFR activity and various readouts of the network. This model shows that 5mTHF levels 
decrease as MTHFR activity decreases, reflecting the effects of the MTHFR C677T polymorphism (Table 1). The 
current model also recapitulates the biological observation that decreased MTHFR activity results in accumu-
lation of 10fTHF and THF (Table 1). Inclusion of 10fTHF in the folate distribution is a strength of the current 
model in that it allows for estimation of the effect that perturbations to the system have on accumulation of this 
unstable form of folate, which likely accounts for the decreased folate status linked to NTDs in carriers of the 
polymorphism30, 32.
Figure 2. Steady states for five different values of glycine (folate cycle in % and the homocysteine remethylation 
cycle in μM). Where possible, a trend arrow is provided on the right to show the experimental outcome 
observed in Herbig et al.28. All the trends are consistent with literature (green arrows) except for the total % of 
5 mTHF in the glycine range 5–10 mM (red arrow).
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SAM and SAH levels vary markedly with changes in MTHFR activity (SAM levels decrease and SAH levels 
increase by more than 50% when comparing the “CC” model to the “TT” model), with a SAM/SAH ratio around 
one being achieved in CC homozygotes compared to 0.24 in TT homozygotes (Table 2). Although methylation 
potential, otherwise known as the SAM/SAH ratio, changes markedly with varying MTHFR activity, homocyst-
eine concentrations appear relatively insensitive to changes in MTHFR in this model (Table 2), inconsistent with 
known effects of the MTHFR TT genotype in elevating serum homocysteine levels41. However, in this model the 
lack of elevation in homocysteine due to the MTHFR C677T polymorphism reflects that the model represents a 
closed system leading to intracellular conversion of cellular homocysteine to SAH as opposed to export of homo-
cysteine into the circulation (Table 2).
The activity of each enzyme in the FOCM network as predicted by the current model indicates that accumula-
tion of 10fTHF resulting from decreased MTHFR activity is due to two factors: (1) an increased flux through both 
the 10fTHF synthetase activity leading to increased synthesis (FTS), and (2) an increased flux through the cyclo-
hydrolase/dehydrogenase activity of MTHFD1 which converts CH2F to CHF to 10fTHF (MTCH, MTD activ-
ities, respectively, Table 3). Interestingly, the accumulation of 10fTHF does not affect flux through the enzymes 
that use 10fTHF as a co-factor for de novo purine synthesis (PGT, AICART; Table 4). This is consistent with 
empirical experimental findings that increasing cellular levels of 10-formytetrahydrofolate dehydrogenase, which 
consumes 10fTHF, do not affect de novo purine synthesis42. Flux through the de novo dTMP synthesis pathway 
increases with decreasing MTHFR activity, consistent with empirical studies indicating these two pathways com-
pete for CH2F (Table 4, columns DHFR, TYMS and SHMT)43. These findings are in agreement with empirical 
data showing that the TT polymorphism results in an increase in CH2F available for dTMP synthesis as indicated 
by isotope tracer studies in humans26.
% THF 10fTHF CHF CH2F DHF
5mTHF
free bound total
MTHFR x2 0.25 14.43 2.86 0.79 0.01 33.45 48.20 81.65
MTHFR x1 – CC 0.70 39.24 7.69 1.93 0.04 8.07 42.34 50.42
MTHFR x0.7 
– CT 1.59 48.76 9.45 2.18 0.04 3.37 34.61 37.98
MTHFR x0.5 3.13 54.53 10.51 2.32 0.04 1.86 27.60 29.46
MTHFR x0.3 
– TT 8.12 58.72 11.26 2.40 0.04 0.90 18.56 19.46
Table 1. Distribution of folate (in percentage of total folate) for different levels of MTHFR activity (ranging 
from 2x to 0.3x of wild type). CC, CT and TT refer to the C677T polymorphism.
µM THF 10fTHF CHF CH2F DHF
5 mTHF Unbound 
SHMT HCY MET SAM SAHfree bound total
MTHFR x2 0.04 2.58 0.51 0.14 0.00 5.97 8.60 14.57 0.40 3.10 37.99 78.41 31.01
MTHFR x1 
– CC 0.12 7.00 1.37 0.34 0.01 1.44 7.56 9.00 1.44 3.47 42.44 51.34 53.26
MTHFR x0.7 
– CT 0.28 8.70 1.69 0.39 0.01 0.60 6.18 6.78 2.82 3.67 43.00 34.87 68.98
MTHFR x0.5 0.56 9.73 1.88 0.41 0.01 0.33 4.93 5.26 4.07 3.78 42.59 26.72 77.42
MTHFR x0.3 
– TT 1.45 10.48 2.01 0.43 0.01 0.16 3.31 3.47 5.69 3.89 41.87 20.47 84.29
Table 2. Concentrations of model variables (in µM) for different levels of MTHFR activity (ranging from 2x to 
0.3x of wild type). CC, CT and TT refer to the C667T polymorphism.
µM/h FTS
MTCH MTD
MTHFR MTR
Unbinding 
of SHMT 
and 5mTHF10fTHF → CHF CHF → 10fTHF CHF → CH2F CH2F → CHF
MTHFR x2 13,101.4 332,703.8 330,313.4 37,733.2 35,342.8 26.8 26.8 17,035.2
MTHFR x1 
- CC 23,582.5 756,270.3 744,706.4 89,938.7 78,374.9 21.6 21.6 14,964.5
MTHFR x0.7 
- CT 31,430.7 884,173.6 864,936.0 106,222.3 86,984.7 16.0 16.0 12,231.1
MTHFR x0.5 36,054.6 954,589.4 930,806.0 115,378.8 91,595.3 11.7 11.7 9,754.6
MTHFR x0.3 
- TT 39,755.7 1,002,680.1 975,243.2 121,653.1 94,216.2 7.1 7.1 6,559.7
Table 3. Fluxes of the reactions catalyzed by the enzymes FTS, MTCH, MTD, MTHFR and MTR and the 
binding of 5mTHF and SHMT for different levels of MTHFR activity (ranging from 2x to 0.3x of wild type). CC, 
CT and TT refer to the C667T polymorphism.
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5mTHF binds to and is a potent inhibitor of SHMT and glycine N-methyltransferase (GNMT). Decreased 
MTHFR activity, which lowers cellular 5mTHF levels (Table 2), increases the flux through the SHMT1-catalyzed 
reaction in the direction of serine catabolism to glycine (Table 4). This reflects the depletion of intracellular 
5mTHF as well as glycine, resulting from increased GNMT activity that results from 5mTHF depletion (Table 5). 
Methionine synthase (MTR) flux is highly sensitive to MTHFR genotype reflecting its dependence on availability 
of its substrate 5mTHF that is generated by MTHFR (Table 3).
The MTHFR C677T variant affects both CH2F partitioning (between homocysteine remethylation and dTMP 
biosynthesis) and intracellular folate concentrations; the 677 T variant lowers intracellular folate levels. Therefore, 
the impact of this variant on FOCM was modeled at two different levels of folate (Tables 6–10) (folate replete 
conditions, 18 μM, and low-folate conditions, 9 μM) to understand how the variants function within the FOCM 
network as a function of folate cofactor availability. The results demonstrate that the changes in the percentage of 
5mTHF (as well as other major one-carbon forms of folate) are more pronounced in the TT genotype than in the 
CC genotype when cellular folate levels are decreased (Table 6). The percentage of 5 mTHF in CC homozygous 
does not change in the folate replete and deficiency states, whereas the accumulation of 5 mTHF in TT homozy-
gotes differs between the deficient and replete states (Table 6).
Fluxes through FOCM pathways are affected by both the MTHFR C677T polymorphism and folate levels. 
The most sensitive pathways to folate deficiency are the MTCH and MTD activities of MTHFD1, MTHFR, 
MTR, DNMT, DHFR, and TYMS (Tables 8–10, row showing absolute flux differences between folate levels). Flux 
through the dTMP synthesis pathway (DHFR and TYMS) is highly sensitive to folate status for both the MTHFR 
CC and TT genotypes (Table 9), with the TT homozygotes being the most sensitive. Flux through GNMT was 
µM/h PGT AICARFT DHFR TYMS
SHMT Binding 
of 
SHMT 
and 
5 mTHFCH2F → THF THF → CH2F
MTHFR x2 4,406.3 6,304.6 113.5 113.5 2819.8 569.7 17,035.2
MTHFR x1 
- CC 5,268.8 6,749.8 263.4 263.4 15,646.6 4,367.7 14,964.5
MTHFR x0.7 
- CT 5,388.7 6,804.3 295.0 295.0 31,989.8 13,063.2 12,231.1
MTHFR x0.5 5,442.7 6,828.4 312.3 312.3 47,127.3 23,667.8 9,754.6
MTHFR x0.3 
- TT 5,475.7 6,843.0 322.1 322.1 66,523.2 39,415.5 6,559.7
Table 4. Fluxes of the reactions catalyzed by the enzymes PGT, AICARFT, DHFR, TYMS, SHMT and the 
unbinding of 5mTHF and SHMT for different levels of MTHFR activity (ranging from 2x to 0.3x of wild type). 
CC, CT and TT refer to the C667T polymorphism.
µM/h BHMT MAT-I
MAT-
III GNMT DNMT
SAHH
SAH → HCY HCY → SAH
MTHFR x2 145.9 110.3 62.4 119.6 127.4 264.6 91.9
MTHFR x1 
- CC 161.0 123.0 59.6 370.9 87.2 285.2 102.6
MTHFR x0.7 
- CT 168.3 127.9 56.3 593.3 59.6 292.4 108.2
MTHFR x0.5 172.1 129.3 54.4 723.1 45.6 295.2 111.5
MTHFR x0.3 
- TT 175.5 129.8 52.7 830.4 34.7 297.1 114.5
Table 5. Fluxes of the reactions catalyzed by the enzymes MTR, BHMT, MAT-I, MAT-III, GNMT, DNMT and 
SAHH for different levels of MTHFR activity (ranging from 2x to 0.3x of wild type). CC, CT and TT refer to the 
C667T polymorphism.
% THF 10fTHF CHF CH2F DHF
5 mTHF
free bound total
low folate
CC 1.27 38.48 7.46 1.65 0.03 4.98 46.13 51.11
TT 4.24 49.75 9.45 1.68 0.03 0.93 33.91 34.84
replete folate
CC 0.70 39.24 7.69 1.93 0.04 8.07 42.34 50.42
TT 8.12 58.72 11.26 2.40 0.04 0.90 18.56 19.46
Table 6. Distribution of folate (in percentage of total folate) for replete (18 µM) and low (9 µM) levels of total 
folate and for the CC and TT case of the C667T MTHFR polymorphism.
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also highly sensitive to folate status in the CC homozygotes, whereas GNMT flux in TT homozygotes was insen-
sitive to folate status (Table 10). Similar but less pronounced effects were seen for flux through SHMT (Table 9).
To understand if MTHFR genotype affects the stability of the FOCM network at steady state, the determin-
istic simulation was coupled with stochastic simulation using a hybrid simulation strategy (see Methods and 
Supplementary Material). Model steady states were obtained under four different conditions that differed by 
MTHFR 677 genotype (CC and TT case) and intracellular folate levels (replete and low). Interestingly, the most 
stable steady state (the one with lowest total sum of reaction propensities a0(x), see Methods for details), was the 
CC case with folate replete concentrations, consistent with numerous epidemiological studies associating the 
MTHFR C677T genotype with folate-related pathologies (Table 11)43. The enzyme that exhibited the greatest level 
of stochasticity in response to folate levels and/or the MTHFR C677T polymorphism was SHMT1 (Table S6).
The molecular basis of uracil misincorporation into DNA. Mouse models implicate SHMT1 and 
impaired de novo dTMP synthesis in NTD risk. Impaired de novo dTMP synthesis causes an increase in dUMP, 
which when converted to dUTP causes uracil misincorporation into DNA because DNA polymerases do not dis-
tinguish between dTTP and dUTP44. The dTMP biosynthesis pathway enzymes (MTHFD1, SHMT, TYMS, and 
DHFR) are present in both the cytosol and recently have been found to function in the nucleus. In the nucleus, 
they comprise a multi-enzyme complex at sites of DNA synthesis that may be critical to limit rates of uracil mis-
incorporation into DNA, but regulatory mechanisms remain unknown45. These enzymes are modified by the 
Small Ubiquitin-like MOdifier (SUMO) protein at the G1/S boundary, which permits their nuclear translocation 
during S-phase of the cell cycle46. One study showed that when nuclear translocation of this complex is impaired 
µM/h FTS
MTCH MTD
MTHFR MTR10fTHF → CHF CHF → 10fTHF CHF → CH2F CH2F → CHF
CC
replete folate 23,582.5 756,270.3 744,706.4 89,938.7 78,374.9 21.6 21.6
low folate 22,583.6 427,359.0 415,960.1 48,054.6 36,655.7 13.8 13.8
absolute difference (% of 
replete folate) 4.2 43.5 44.1 46.6 53.2 36.5 36.5
TT
replete folate 39,755.7 1,002,680.1 975,243.2 121,653.1 94,216.2 7.1 7.1
low folate 33,618.2 529,771.1 507,690.2 59,371.2 37,290.2 4.2 4.2
absolute difference (% of 
replete folate) 15.4 47.2 47.9 51.2 60.4 41.2 41.2
Table 8. Fluxes of the reactions catalyzed by the enzymes FTS, MTCH, MTD, MTHFR and MTR for replete 
(18 µM) and low (9 µM) levels of total folate and for the CC and TT case of the C677T MTHFR polymorphism.
µM/h PGT AICARFT DHFR TYMS
SHMT Binding 
of 
5 mTHF 
and 
SHMT
Unbinding of 
5 mTHF and 
SHMTCH2F → THF THF → CH2F
CC
replete folate 5,268.8 6,749.8 263.4 263.4 15,646.6 4,367.7 14,964.5 1,4964.5
low folate 4,711.3 6,473.4 117.8 117.8 18,535.4 7,268.2 8150.7 8150.7
absolute difference (% of 
replete folate) 10.6 4.1 55.3 55.3 18.5 66.4 45.5 45.5
TT
replete folate 5,475.7 6,843.0 322.1 322.1 66,523.2 39,415.5 6,559.7 6,559.7
low folate 4,943.9 6,593.4 120.0 120.0 73,586.0 51,629.1 5,992.1 5,992.1
absolute difference (% of 
replete folate) 9.7 3.6 62.8 62.8 10.6 31.0 8.7 8.7
Table 9. Fluxes of the reactions catalyzed by the enzymes PGT, AICARFT, DHFR, TYMS and SHMT and the 
binding/unbinding of 5 mTHF and SHMT for replete (18 µM) and low (9 µM) levels of total folate and for the 
CC and TT case of the C677T MTHFR polymorphism.
μM THF 10fTHF CHF CH2F DHF
5 mTHF Free 
SHMT HCY MET SAM SAHfree bound total
low folate
CC 0.11 3.43 0.67 0.15 0.00 0.44 4.12 4.56 2.55 3.73 42.84 30.34 73.61
TT 0.38 4.44 0.84 0.15 0.00 0.08 3.03 3.11 10.00 3.95 41.35 17.43 87.79
replete folate
CC 0.12 7.00 1.37 0.34 0.01 1.44 7.56 9.00 1.44 3.47 42.44 51.34 53.26
TT 1.45 10.48 2.01 0.43 0.01 0.16 3.31 3.47 5.69 3.89 41.87 20.47 84.29
Table 7. Concentrations of model variables (in µM) for replete (18 µM) and low (9 µM) levels of total folate and 
for the CC and TT case of the C667T MTHFR polymorphism.
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in a mouse model over-expressing SHMT1, rates of uracil misincorporation into DNA increased several fold45. In 
this model, SHMT1 protein levels were elevated several fold in the liver, yet its localization was restricted to the 
cytoplasm and nuclear SHMT1 levels were depleted compared to wild-type mice45. Furthermore, nuclei isolated 
from SHMT1 overexpressing mice exhibited lower rates of de novo dTMP synthesis compared to nuclei isolated 
from wild-type mice45. This suggests that de novo dTMP synthesis occurs when the enzymes are present in the 
multi-enzyme complex within the nucleus in mammals. However, no definitive experiment has been performed 
that identifies the relative contribution of nuclear and cytosolic dTMP synthesis to overall dTMP synthesis. 
Interestingly, S. cerevesiae do not import the dTMP synthesis pathway into the nucleus47.
To determine if nuclear import of the de novo dTMP pathway was required to meet cellular demands for 
dTTP during DNA replication, rates of dTMP synthesis were modeled for mammalian cells using standard 
Michaelis-Menten kinetics (Table 12; Table 4). Based on the number of A-T base pairs in the human genome 
and an 8-hour S-phase in embryonic stem cells (S-phase in L1210 cells is also 6–10 h48, 49), the rate of dTMP 
synthesis required for faithful cell replication is 7.8 µM/min (calculations are in Supplementary Material, see 
also Table 12)50, 51. In the current model, which does not account for SHMT1/TYMS/DHFR/MTHFD1 nuclear 
localization nor complex formation, cytosolic dTMP synthesis rates are 4.4 µM/min (Table 4, DHFR and TYMS 
flux, 263.4 µM/h, assuming MTHFR 677 CC genotype). This computational deficit between dTMP requirements 
and dTMP synthesis rates suggests that dTMP synthesis as currently modeled in the cytosol where the enzymes 
are not present in a complex cannot meet cellular needs. Nuclear localization and complex formation of the de 
novo dTMP synthesis complex seem to be unique to mammalian cells. In S. cerevesiae, TYMS is not SUMOylated 
and localizes to the nuclear periphery47. The measured rate of dTMP synthesis in S. cerevesiae is 1.8 µM/min52 
(Table 12). The rate of dTMP synthesis required to replicate the S. Cerevesiae genome over the course of an S-phase 
(less than one hour52, 53) is 0.5 µM/min, indicating that yeast synthesize dTMP at a rate that is more than 3-fold 
greater than necessary for adequate dTMP synthesis (calculations are in Supplementary Material). Furthermore, 
in response to DNA damage, yeast increase dNTP concentrations 6–8 fold54 and E. coli increase dNTP concentra-
tions 1.8–3.7 fold55, but dNTP concentrations do not increase after DNA damage in mammals56, 57.
Discussion
Understanding the dynamics of FOCM and its responsiveness to both genetic and environmental perturbations 
is the key to understanding the etiology of folate-related pathologies. Computational models and related simula-
tions permit an identification of the most sensitive reactions within the network that exhibit the greatest degree 
of stochastic behavior leading to variability in network outputs. Furthermore, computational models allow an 
understanding of how both genetics and environmental factors can enhance or repress stochastic behavior at 
defined locations within the network, accelerating the development of diagnostics to identify those at risk for 
folate-related pathologies as well as lead to the development of targeted nutritional interventions for disease 
prevention.
The Shmt1 knockout mouse model (Shmt1+/−, Shmt1−/− embryos) exhibits impaired de novo dTMP synthesis 
in the absence of perturbations of homocysteine remethylation. It also recapitulates risk for NTDs in humans. 
µM/h BHMT MAT-I MAT-III GNMT DNMT
SAHH
SAH → HCY HCY → SAH
CC
replete folate 161.0 123.0 59.6 370.9 87.2 285.2 102.6
low folate 170.3 128.8 55.3 664.0 51.8 294.0 110.0
absolute difference (% of replete 
folate) 5.8 4.7 7.3 79.0 40.5 3.1 7.2
TT
replete folate 175.5 129.9 52.7 830.4 34.7 297.1 114.5
low folate 177.4 129.8 51.8 884.4 29.4 297.9 116.3
absolute difference (% of replete 
folate) 1.1 0.0 1.8 6.5 15.2 0.3 1.6
Table 10. Fluxes of the reactions catalyzed by the enzymes BHMT, MAT-I, MAT-III, GNMT, DNMT and 
SAHH for replete (18 µM) and low (9 µM) levels of total folate and for the CC and TT case of the C677T 
MTHFR polymorphism.
a0(x) replete folate low folate
Difference (% of 
replete folate)
CC 1.6054 · 1015 2.0970 · 1015 30.62
TT 8.5915 · 1015 1.0141 · 1016 18.03
Difference (% 
of CC) 435.15 383.59
Table 11. Total propensities obtained in four steady state conditions according to folate polymorphism (CC 
and TT case) and total concentration of available folate (replete, 18 µM; low, 9 µM). To help comparisons, the 
differences between CC and TT (in % of CC) and between replete and low total folate (in % of replete folate) are 
indicated. A steady state that is less stable (or more noisy) than another one has higher total propensity.
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Specifically, the mouse model exhibits folate-responsive NTDs that occur with minimal perturbation in FOCM, 
and exhibit low and variable penetrance33, 34. In fact, most if not all, folate-related pathologies whose etiology 
involves interactions among genetic risk variants and nutrient exposures also exhibit low and/or variable clin-
ical presentation. Understanding the stochastic behavior of the various reactions within FOCM that results in 
increased variability in FOCM network outputs is essential to understand which enzymes in the network contrib-
ute to folate-related pathologies.
Existing FOCM models rely on the limited quantity of kinetic data present in the literature, and the perfor-
mance of the model will be dependent upon the kinetic parameters chosen to include in the model. Much of the 
available kinetic data for FOCM enzymes present in the literature was collected using the commercially available 
monoglutamate folate substrates, with few studies using the physiologically relevant polyglutamate forms of the 
cofactor. In the cell, newly transported monoglutamate folates are converted to folate polyglutamates, containing 
3 to 7 polyglutamate moieties, though the action of folylpolyglutamate synthetase58. The polyglutamate chain 
(N = 3 glutamate and higher) increases the affinity of folate cofactors for many folate-dependent enzymes by one 
to two orders of magnitude39, 40. Models that include kinetic parameters derived from the use of folate monoglu-
tamates can limit model reliability. Here we established a hierarchy of criteria to select a more homogeneous set 
of kinetic parameters (i.e. Km and Vmax) by referring, when possible, to L1210 cells because of the richness and 
quality of the data used to derive kinetic parameters. Furthermore, our preference was to select kinetic coefficients 
generated using folate polyglutamate cofactors and purified proteins from animal models closest to humans, as 
the variability in kinetic parameters among mammals is much less than the differences observed between folate 
monoglutamate and polyglutamate cofactor substrates.
The current model was validated by demonstrating that it recapitulates empirical observations regarding the 
impact of intracellular glycine on behavior of the FOCM network (Fig. 2). The validated model was then used to 
understand how the MTHFR C677T polymorphism, a known genetic risk factors for NTDs in humans, affects 
FOCM. This model shows that the lower levels of 5mTHF associated with the MTHFR 677 T variant are accom-
panied by elevated levels of 10fTHF, which has been observed in animal models and in humans27–29 (Table 1). The 
model also indicates that 10fTHF accumulates in TT homozygotes as a result of increased flux through both the 
synthetase activity of MTHFD1 (FTS activity, Table 3), but also due to increased flux through MTHFD1 activity 
in the direction converting CH2F to 10fTHF (Table 3). Therefore, the model accurately predicts perturbations in 
FOCM that have been observed in human clinical and epidemiological studies. A recent study suggested that the 
risk of the MTHFR C677T polymorphism for NTDs was due to its known effect on lowering intracellular folate 
concentrations, rather than its role in providing 5 mTHF for homocysteine remethylation32. This model demon-
strates that the MTHFR C677T polymorphism elevates levels of 10fTHF, which is known to be a chemically 
unstable form of folate that is susceptible to oxidative degradation, providing a mechanism by which the MTHFR 
C677T polymorphism depletes intracellular folate levels. Importantly, the model reported here demonstrates that 
the de novo dTMP biosynthesis enzymes are the most sensitive to low intracellular folate concentrations, with 
both DHFR and TYMS activities being repressed by 63% (Table 9). This finding is consistent with the finding 
that mouse models with impaired de novo dTMP biosynthesis are susceptible to NTDs in folate deficiency34. The 
hybrid stochastic simulation also reveals that both folate deficiency and the MTHFR C677T polymorphism create 
overall instability in the network (Table 11), consistent with a vast body of literature demonstrating an associa-
tion of both folate deficiency and the MTHFR C677T polymorphism with various pathologies24, 30. Interestingly, 
SHMT1 exhibits the greatest increase in stochastic behavior as a result of the MTHFR C677T polymorphism 
(Table S6); the SHMT1 enzyme is the only FOCM enzyme that when disrupted results in folate-responsive 
NTDs34.
The primary findings of this study are that the FOCM network is destabilized as a result of folate deficiency 
and the MTHFR677T polymorphism, and that SHMT is the most sensitive enzyme within the network to this net-
work instability. This finding nicely connects the MTHFR genetic variant, a known risk factor for human NTDs, 
and SHMT1, the only folate enzyme whose disruption results in folate-responsive NTDs in mice. Furthermore, 
this model predicts that de novo dTMP synthesis rates in mammals are about half of what is required to meet 
DNA replication demands for dTMP (Table 12). Although mammals contain two pathways for dTMP synthesis, 
Human S. cerevesiae
Genome size 3.0 × 109 bp 1.2 × 107 bp
% AT 59% 61.5%
T bases needed for 
replication
1.77 × 109 
molecules
7.5 × 106 
molecules
Length of cell cycle 24 h 2.5 h
Length of S-phase 8 h 0.83 h
Cell volume 8 × 10
−13 L (ES 
cell) 5 × 10
−14 L
dTMP synthesis rate required 
to replicate genome 7.8 µM/min 0.5 µM/min
Measured dTMP synthesis 
rate (model outcomes) 4.4 µM/min 1.8 µM/min
Ratio of dTMP production 
relative to dTMP required for 
replication
0.6 3.6
Table 12. Cellular capacity for de novo dTMP synthesis in mammals and yeast at S-phase.
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the folate-dependent de novo dTMP synthesis pathway described here and a salvage pathway catalyzed by thy-
midine kinase 1, the salvage pathway activity is insufficient to meet cellular needs based on observations that 
folate deficiency results in elevated uracil accumulation in DNA. In mammalian cells, the de novo dTMP syn-
thesis enzymes form a multi-enzyme complex that interacts with DNA replication enzymes46. The discrepancy 
between de novo dTMP synthesis rates required to replicate the genome and the rate of dTMP synthesis currently 
predicted by the model indicates that the model should be extended to include multi-enzyme complex formation 
and substrate channeling in the nucleus to model more accurately determinants of FOCM and dTMP synthesis. 
The inclusion of the dTMP multi-enzyme metabolic complex in the model is expected to limit substrate diffusion 
and increase the rate of dTMP synthesis.
Methods
Description of the Model and of the Simulation Techniques. The model was constructed as a closed 
system using the subset of reactions that describe the FOCM pathways and homocysteine remethylation in cyto-
plasm19 (Fig. 1). For the simulation, we employed a hybrid stochastic approach using deterministic simulation to 
compute the initial phase of the dynamics until a model steady state was reached, and then we assessed the stabil-
ity of the achieved steady state by relying on exact stochastic simulation. We adopted a hybrid approach, rather 
than one entirely based on exact stochastic simulation59, because of the intensive computational effort introduced 
by the stiffness of the system during the simulation.
The deterministic simulation was based on ODEs, where reactions were described in terms of 
Michaelis-Menten equations consistent with the original model of Reed19 and computed using the MATLAB 
integrator ode15s, whereas parameter estimates were derived from literature or calculated by nonlinear least 
squares optimization. The kinetic constants were obtained from folate polyglutamate cofactors and their inter-
action with enzymes purified from L1210 cells where possible and otherwise from other mammalian tissue (see 
Supplementary Material for a detailed discussion of the model and parameter estimates).
The set of ODEs was further translated into a stochastic reaction-based model and a hybrid simulation 
approach60 was employed to quantify the level of stochasticity in the considered FOCM steady states. We refer to 
the Supplementary Material for a detailed description of how the ODE model has been translated to a reaction 
based stochastic one. According to the seminal work of Gillespie59, exact stochastic simulation allows simulation 
of each reaction event asynchronously when such reaction event is most probable to occur. To allow this, the 
simulation algorithm computes a propensity function aj(x) at each simulation step for each modeled reaction Rj, 
where x is the current state of the system providing the abundances of all modeled species at the considered time. 
The propensity value of a reaction has a direct link with the probability of its execution, that is, reactions with 
higher propensity are more likely to be fired in the near future. To evaluate when the next reaction event will 
occur, also the total sum of propensities = ∑a x a x( ) ( )R j0 j  is computed, because this quantity is linked to the 
number of reaction events occurring in the next time unit, that is, with increasing total propensity the number of 
reaction events per unit of time also increases. In Table 11, we provide the total sum of propensities for the con-
sidered steady states. On average, we would need to generate up to 1015–1016 reaction events per unit of time 
during the stochastic simulation, due to stiffness of the system. To circumvent the problem, we relied on the 
concept of total propensity to evaluate the stability of the steady state, by assuming that a steady state is more 
stable when it has a lower value of a0(x), that is, a lower averaged number of reaction events that can perturb the 
equilibrium of the steady state.
Model validation. To validate the FOCM model, in silico experiments were performed to determine if the 
model could recapitulate empirical data generated in MCF-7 cells by Herbig et al.10 focusing on the effect of gly-
cine on FOCM (Fig. 2). Glycine is important because, as a second substrate, it has a direct influence on the reac-
tion catalyzed by the enzymes GNMT as well as on the reversible reaction transforming CH2F to THF catalyzed 
by the enzyme SHMT. The purpose is to understand how the steady state of FOCM is affected by altering intracel-
lular glycine concentrations. This was achieved by running several model simulations starting from different gly-
cine concentrations and comparing the corresponding steady states with empirical data from Herbig et al.10. This 
study examined the effect of exogenous glycine at concentrations from 0 to 10 mM on the relative distribution of 
folate one-carbon forms as well as S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels. In 
summary, the empirical data revealed that as glycine concentrations increase intracellular 10fTHF levels increase 
at the expense of 5mTHF levels that decrease. Furthermore, as glycine concentrations increase SAM levels are 
depleted and SAH levels rise. These changes were interpreted by the effects of glycine concentration driving the 
reversible SHMT reaction in the direction of serine synthesis10.
We simulated the effect of glycine on folate distribution, SAM, and SAH concentrations using the computa-
tional model for values of glycine ranging from 0 to 10 mM (Fig. 2). The trends obtained by the model simula-
tions were in agreement with the literature (green arrows in Fig. 2), confirming the coherence between model 
outcomes and empirical data. We observed only one exception related to the total % of 5 mTHF at 10 mM glycine 
(red arrow in Fig. 2). This discrepancy could be mainly due to two reasons: (1) 10 mM glycine is an extreme and 
non-physiological intracellular glycine concentration that could cause pharmacological effects, (2) the large mag-
nitude of the experimental error in the Herbig et al. study at this glycine concentration.
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